Johnson & Johnson is advancing Alzheimer’s research through precision medicine, focusing on tau-targeting therapies like ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

COVID-19, even in mild cases, is linked to changes in Alzheimer’s disease-related brain biomarkers comparable to four years ...

The first participants in an international clinical trial aimed at preventing Alzheimer's disease in young adults at high risk of the disease have been enrolled.

Our grey matter has always been a mystery, even to neurologists, but Professor Masud Husain says life-changing advances may ...

In July 2024, the FDA approved a third antibody for Alzheimer ... and increased accretion of amyloid and tau, which in turn leads to neurodegeneration. To tackle presumably harmful neuroinflammation ...

In July 2024, the FDA approved a third antibody ... of amyloid and tau, which in turn leads to neurodegeneration. To tackle presumably harmful neuroinflammation and protein build-up, scientists ...

As of September 30, 2024, Alector had $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide runway through 2026. Alector plans to provide ...

The number of people living with neurological disorders, such as Alzheimer’s disease, epilepsy, multiple sclerosis and ...